Feasibility, tolerability and efficacy of the ketogenic diet in children with drug-resistant epilepsy in Vietnam.
Vietnam
children
feasibility
ketogenic diet
tolerability
Journal
Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
27
01
2023
accepted:
27
08
2023
medline:
4
12
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
According to the WHO, more than 50 million people have epilepsy. Among them, nearly 80% of patients with epilepsy live in developing countries and 75% of them do not have access to treatment. The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy. Although it has been studied in Asia, no such studies have been conducted in Vietnam. The purpose of this study was to verify the feasibility and tolerability of KD in children with refractory epilepsies in Vietnam. Children with drug-resistant epilepsy followed at Children's Hospital, Vietnam treated by KD were included in a prospective study from June 2019 to October 2021. Side-effects, retention rate, number, and duration of seizures were recorded after 1, 3, 6, 9 and 12 months of KD. Patients were considered as respondents when a 50% seizure frequency was reached. Tolerance and acceptability of the KD were closely monitored. Forty-six children were included but KD was contraindicated for one patient. Due to the COVID pandemic, we had to rely on internet exchanges to stay in touch with families. Meals had to be adapted to Vietnamese culinary habits. The retention rate decreased from 82.2% at 1 month to 40% at 12 months of follow-up. The incidence of side effects was 44.4% and occurred mainly during the first month. Fifteen patients out of 45 were considered as responders after 12 months. Our study was the first attempt to introduce KD in Vietnam. It demonstrated that this diet was feasible and well tolerated. The KD diet resulted in significant improvement for 30% of our patients with drug-resistant epilepsy. This percentage is lower than in some studies but warrants the use of KD as a valuable alternative in a country where many patients lack access to recent treatments.
Identifiants
pubmed: 37712338
doi: 10.1002/epi4.12825
pmc: PMC10690654
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1484-1490Subventions
Organisme : La Fondation Française pour la Recherche sur l'Epilepsie
Informations de copyright
© 2023 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Epilepsia. 2015 Sep;56(9):1337-42
pubmed: 26033161
Epilepsia. 2015 Oct;56(10):1515-23
pubmed: 26336950
Transl Pediatr. 2020 Aug;9(4):561-566
pubmed: 32953554
Nutrients. 2020 Jan 24;12(2):
pubmed: 31991539
Seizure. 2009 Jul;18(6):446-9
pubmed: 19427240
Epilepsia. 2015 Aug;56(8):1185-97
pubmed: 26122601
Seizure. 2018 Aug;60:144-148
pubmed: 29990707
J Med Assoc Thai. 2016 Feb;99(2):159-65
pubmed: 27249895
Epilepsia. 2010 Jun;51(6):1069-77
pubmed: 19889013
Am J Med Genet A. 2022 Jul;188(7):2048-2060
pubmed: 35365919
Nutrients. 2021 Apr 09;13(4):
pubmed: 33918854
Epilepsia. 2005 Feb;46(2):272-9
pubmed: 15679508
Epilepsia Open. 2022 Mar;7(1):11-26
pubmed: 34882995
Epilepsia. 2006 Feb;47(2):330-4
pubmed: 16499757
Epilepsia Open. 2018 May 21;3(2):175-192
pubmed: 29881797
Epilepsia Open. 2023 Dec;8(4):1484-1490
pubmed: 37712338
Epilepsy Behav Case Rep. 2018 Nov 23;11:35-38
pubmed: 30619711
Epilepsia. 2009 Oct;50(10):2320-3
pubmed: 19744115